Atlas Trials

Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma

Clinical trial NCT05344833 · RECRUITING

Trial details

NCT number
NCT05344833
Sponsor
University of Illinois at Chicago
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2023-01-05
Primary completion
2030-12-01
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.